— DJS Antibodies’ DJS-002 is a potential first-in-class antibody directed to LPAR1, currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases
— The company’s proprietary HEPTAD platform will extend AbbVie’s current discovery research capabilities by generating potential novel antibodies against difficult-to-drug protein targets in immunology and beyond
NORTH CHICAGO, IL, USA I October 20, 2022 I AbbVie (NYSE: ABBV) today announced the acquisition of DJS Antibodies Ltd (“DJS”), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS’s lead program is DJS-002, a potential first-in-class lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. IPF is an aggressive, high mortality disease caused by fibrotic scarring in the lungs and remains an area of high unmet medical need.
“We are excited to bring the innovative science behind DJS-002 and the talented team at DJS to AbbVie,” said Jonathon Sedgwick, Ph.D., vice president and global head of discovery research, AbbVie. “This acquisition will deliver new capabilities to enhance our current antibody research activities, an opportunity to strengthen our immunology portfolio, and provide a strong foothold for expanded research efforts in the dynamic bioscience hub in Oxford, UK.”
DJS’s proprietary HEPTAD platform is a novel approach to antibody discovery with specific capabilities targeting transmembrane protein targets. A key benefit of this acquisition is for AbbVie, through DJS, to access the HEPTAD platform as a complement to its current robust capabilities in biotherapeutics research. DJS will leverage AbbVie’s extensive drug discovery expertise to continue generating antibody therapeutics and novel biology insights against targets like GPCRs, which have previously been intractable to biologics approaches.
“DJS was built on the principles of scientific curiosity and an aspiration to discover clinically meaningful innovative medicines. We’ve been privileged to grow the company within the world-class scientific and entrepreneurial community of Oxford, from an initial concept through to a successful biotech comprising an extremely talented team,” said David Llewellyn and Joe Illingworth, co-founders of DJS. “The whole team is incredibly excited to take the next step in this journey with AbbVie as we work together to accelerate the translation of our lead program into the clinic and develop an exciting research center here in the UK.”
Under the terms of the agreement, AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS. DJS shareholders remain eligible for potential additional payments upon the achievement of certain development milestones related to the success of the DJS-002 program. AbbVie anticipates retaining all current DJS employees and its facility in Oxford.
DJS is backed by founding investors Oxford Science Enterprises and Johnson & Johnson Innovation Ltd., along with LifeArc, Sedgwick Yard and Amgen Ventures.
DJS and its shareholders were advised by Centerview (Financial Advisor). Goodwin Procter LLP (Legal) advised DJS and its shareholders on the transaction, and Cooley LLP (Legal) advised DJS on other corporate matters including providing additional support on the transaction.
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
About DJS Antibodies
Based in Oxford, UK, DJS Antibodies is a biotechnology company dedicated to creating the next generation of antibody therapeutics. DJS Antibodies utilizes their proprietary HEPTAD platform to enable antibody discovery to GPCRs and other intractable targets. Using HEPTAD, the company has generated a unique pipeline including DJS-002, a novel antibody targeting LPAR1 for the treatment of chronic fibrotic diseases. www.djsantibodies.com
SOURCE: AbbVie
Post Views: 520
— DJS Antibodies’ DJS-002 is a potential first-in-class antibody directed to LPAR1, currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases
— The company’s proprietary HEPTAD platform will extend AbbVie’s current discovery research capabilities by generating potential novel antibodies against difficult-to-drug protein targets in immunology and beyond
NORTH CHICAGO, IL, USA I October 20, 2022 I AbbVie (NYSE: ABBV) today announced the acquisition of DJS Antibodies Ltd (“DJS”), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS’s lead program is DJS-002, a potential first-in-class lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. IPF is an aggressive, high mortality disease caused by fibrotic scarring in the lungs and remains an area of high unmet medical need.
“We are excited to bring the innovative science behind DJS-002 and the talented team at DJS to AbbVie,” said Jonathon Sedgwick, Ph.D., vice president and global head of discovery research, AbbVie. “This acquisition will deliver new capabilities to enhance our current antibody research activities, an opportunity to strengthen our immunology portfolio, and provide a strong foothold for expanded research efforts in the dynamic bioscience hub in Oxford, UK.”
DJS’s proprietary HEPTAD platform is a novel approach to antibody discovery with specific capabilities targeting transmembrane protein targets. A key benefit of this acquisition is for AbbVie, through DJS, to access the HEPTAD platform as a complement to its current robust capabilities in biotherapeutics research. DJS will leverage AbbVie’s extensive drug discovery expertise to continue generating antibody therapeutics and novel biology insights against targets like GPCRs, which have previously been intractable to biologics approaches.
“DJS was built on the principles of scientific curiosity and an aspiration to discover clinically meaningful innovative medicines. We’ve been privileged to grow the company within the world-class scientific and entrepreneurial community of Oxford, from an initial concept through to a successful biotech comprising an extremely talented team,” said David Llewellyn and Joe Illingworth, co-founders of DJS. “The whole team is incredibly excited to take the next step in this journey with AbbVie as we work together to accelerate the translation of our lead program into the clinic and develop an exciting research center here in the UK.”
Under the terms of the agreement, AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS. DJS shareholders remain eligible for potential additional payments upon the achievement of certain development milestones related to the success of the DJS-002 program. AbbVie anticipates retaining all current DJS employees and its facility in Oxford.
DJS is backed by founding investors Oxford Science Enterprises and Johnson & Johnson Innovation Ltd., along with LifeArc, Sedgwick Yard and Amgen Ventures.
DJS and its shareholders were advised by Centerview (Financial Advisor). Goodwin Procter LLP (Legal) advised DJS and its shareholders on the transaction, and Cooley LLP (Legal) advised DJS on other corporate matters including providing additional support on the transaction.
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
About DJS Antibodies
Based in Oxford, UK, DJS Antibodies is a biotechnology company dedicated to creating the next generation of antibody therapeutics. DJS Antibodies utilizes their proprietary HEPTAD platform to enable antibody discovery to GPCRs and other intractable targets. Using HEPTAD, the company has generated a unique pipeline including DJS-002, a novel antibody targeting LPAR1 for the treatment of chronic fibrotic diseases. www.djsantibodies.com
SOURCE: AbbVie
Post Views: 520
